文献速递骨质疏松与钙磷/甲状旁腺垂体与肾上腺疾病

新型家族性PHP1B变异:GNAS-A/B甲基化不完全缺失伴GNAS-AS2甲基化增强

A Novel Familial PHP1B Variant With Incomplete Loss of Methylation at GNAS-A/B and Enhanced Methylation at GNAS-AS2.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究报道了一个无STX16缺失的常染色体显性PHP1B家系,患者GNAS A/B:TSS-DMR甲基化不完全缺失,而GNAS-AS2:TSS-DMR新发现的AS2-1亚域甲基化升高,AS2-2正常。研究提示GNAS-AS2:TSS-DMR存在两个亚域,其甲基化改变有助于区分PHP1B/iPPSD3变异并指导遗传缺陷搜索。

要点

  • AD-PHP1B患者可无STX16缺失,表现为GNAS A/B:TSS-DMR甲基化不完全缺失。
  • GNAS-AS2:TSS-DMR存在AS2-1和AS2-2两个亚域,甲基化水平不同。
  • 该家系患者AS2-1甲基化升高,AS2-2正常,不同于已知类型。

核心结论

  • 新型GNAS-AS2:TSS-DMR甲基化改变有助于进一步区分PHP1B/iPPSD3变异并指导潜在遗传缺陷的寻找。

研究设计与样本

  • 研究纳入24例患者和10例对照,包括无STX16缺失的AD-PHP1B家系5例、STX16缺失AD-PHP1B 9例、散发性PHP1B 10例、未受累对照10例、patUPD20和matUPD20各1例。
  • 采用焦磷酸测序、甲基化敏感多重连接依赖探针扩增和多重连接依赖探针扩增进行甲基化和拷贝数分析。

主要发现

  • 健康对照GNAS-AS2:TSS-DMR存在AS2-1和AS2-2两个亚域,甲基化分别为16.0±2.3%和31.0±2.2%。
  • 无已知遗传缺陷的AD-PHP1B家系患者GNAS A/B:TSS-DMR甲基化不完全缺失,3个已知母源和父源DMR甲基化正常。
  • 该家系患者AS2-1甲基化升高至32.9±3.5%,而AS2-2甲基化为30.5±2.9%。

临床怎么用

  • 对无STX16缺失的AD-PHP1B患者应评估GNAS-AS2:TSS-DMR甲基化,尤其AS2-1亚域。
  • 识别AS2-1甲基化升高有助于将此类变异与典型AD-PHP1B区分。

局限性

  • 研究仅基于单个家系5例患者,结论需更大样本验证。
  • 未明确该家系的具体遗传缺陷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Pseudohypoparathyroidism type 1B (PHP1B), also referred to as inactivating PTH/PTHrP signaling disorder (iPPSD), is characterized by proximal renal tubular resistance to parathyroid hormone (PTH) leading to hypocalcemia, hyperphosphatemia, and elevated PTH values. Autosomal dominant PHP1B (AD-PHP1B) with loss of methylation at the maternal GNAS A/B:TSS-DMR (transcription start site-differentially methylated region) alone can be caused by maternal deletions involving STX16. OBJECTIVE: Characterize a previously not reported AD-PHP1B family with loss of methylation at GNAS A/B:TSS-DMR, but without evidence for a STX16 deletion on the maternal allele and assess GNAS-AS2:TSS-DMR methylation. METHODS: DNA from 24 patients and 10 controls were investigated. AD-PHP1B patients without STX16 deletion from a single family (n = 5), AD-PHP1B patients with STX16 deletion (n = 9), sporPHP1B (n = 10), unaffected controls (n = 10), patUPD20 (n = 1), and matUPD20 (n = 1). Methylation and copy number analyses were performed by pyrosequencing, methylation-sensitive multiplex ligation-dependent probe amplification, and multiplex ligation-dependent probe amplification. RESULTS: Molecular cloning of polymerase chain reaction-amplified, bisulfite-treated genomic DNA from healthy controls revealed evidence for 2 distinct GNAS-AS2:TSS-DMR subdomains, named AS2-1 and AS2-2, which showed 16.0 ± 2.3% and 31.0 ± 2.2% methylation, respectively. DNA from affected members of a previously not reported AD-PHP1B family without the known genetic defects revealed incomplete loss of methylation at GNAS A/B:TSS-DMR, normal methylation at the 3 well-established maternal and paternal DMRs, and, surprisingly, increased methylation at AS2-1 (32.9 ± 3.5%), but not at AS2-2 (30.5 ± 2.9%). CONCLUSION: The distinct methylation changes at the novel GNAS-AS2:TSS-DMR will help characterize further different PHP1B/iPPSD3 variants and will guide the search for underlying genetic defects, which may provide novel insights into the mechanisms underlying GNAS methylation.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hanna P, Francou B, Delemer B, et al. A Novel Familial PHP1B Variant With Incomplete Loss of Methylation at GNAS-A/B and Enhanced Methylation at GNAS-AS2. J Clin Endocrinol Metab. 2021. PMID: 33677588. doi:10.1210/clinem/dgab136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。